Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Research Partnership announces several new appointments

    June 7, 2017 | Anne Cunningham, Morten Andersen, New appointments, Sue Rees, emerging markets 

    Research Partnership is delighted to welcome Anne Cunningham and Morten Andersen and announce that Sue Rees has joined our specialist Emerging Markets team.

    Anne Cunningham has joined Research Partnership’s European division as a Director at the company’s global head office in London. Anne has over 25 years’ of practise in the pharmaceutical industry and brings with her extensive and wide ranging experience from roles in both client companies including AstraZeneca and on the agency side. Most recently Anne was Customer Insights Partner at AbbVie where she was responsible for leading an integrated programme of analytics, market research and insight generation to support AbbVie’s rheumatology brands. Prior to this she was Research Director at Cello Health Insight.

    Morten Anderson has joined Research Partnership’s specialist quantitative team as an Associate Director. Morten joins us from Kantar Health, where he has spent the last 9 years, with a particular emphasis on large-scale quantitative and brand tracking projects for international clients.

    Commenting on their appointments Mark Jeffery, Founding Director, said, “We are delighted to welcome both Anne and Morten to Research Partnership. Both bring with them a wealth of knowledge and expertise and we look forward to them contributing to the company’s ongoing growth and development as we celebrate our 20th anniversary. Having worked with Anne previously as a client of our syndicated market-tracking tool Therapy Watch, it’s great to now be able to welcome her to our ad-hoc team.”

    Director Sue Rees, who first joined Research Partnership in 2013 in the company’s European division, has transitioned into the specialist Emerging Markets Division. Sue has over 25 years’ experience in market research from both agency and client-side.

    Commenting on the move, Marc Yates, Director of Emerging Markets said “The Emerging Markets Division has continued to grow and in order to sustain this growth we needed to recruit a Director who could not only add to the skills of our existing team but hit the ground running. Sue’s knowledge and prior experience of working in the Asia market will be a strong asset to the team.”

    Visit researchpartnership.com to find out more 

    This content was provided by Inizio

    Company Details

    - PMLiVE

    Inizio

    Email
    Website

     Latest Content from  Inizio 

    Inizio Engage CEO Jim Sage featured in pharmaphorum’s “12 Questions” series

    Discover Jim Sage’s insights on leadership, industry challenges, and the transformative impact of data, technology, and patient-centric innovation in his latest pharmaphorum “12 Questions” interview.

    Reframing the Obesity Conversation: Key Takeaways from ObesityWeek® 2025

    As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector collaboration driving innovation. At ObesityWeek® 2025 in Atlanta, experts from across Inizio reflected...

    How DataGateway unified oncology data for real-world insights & market intelligence

    Discover how our DataGateway platform unifies fragmented real-world oncology data into a single, validated dataset that delivers deeper insights and faster decision-making.

    Inizio launches InConcert™ to transform pre-launch planning through connected intelligence.

    Inizio today announced the launch of InConcert™, a new AI-powered data solution designed to accelerate smarter, evidence-led decisions during the critical pre-launch phase of the product lifecycle.

    ESMO 2025 highlights: How storytelling, design & emotion are transforming scientific engagement

    Discover key insights from ESMO 2025 on how design, emotion, and sustainability are reshaping medical congress experiences. Featuring expert takes from Inizio leaders.

    Preparing for ASH 2025: Pharma’s role in hematology innovation

    As the global hematology community prepares for the 67th ASH® Annual Meeting and Exposition, Inizio experts share their perspectives on what’s driving the field forward – and how pharma companies...

    AI without limits: A smarter, integrated approach to Medical Affairs

    At Inizio Medical, we believe AI isn’t replacing Medical Affairs — it’s redefining what’s possible. Our platform, iON.AI™, enhances human expertise, streamlines complex workflows, and strengthens strategic impact through seamless...

    What to expect from Obesity Week 2025: Key trends shaping the future of obesity care

    Discover how Inizio experts are shaping the future of obesity care—where science, strategy, and innovation unite to advance cardiometabolic health and drive real-world impact.

    AI with intent: How Inizio is redefining pharma through precision and partnership

    At Fierce Pharma Week, Inizio revealed how the fusion of human expertise and purposeful AI is reshaping pharma communications and driving real-world impact—discover how this human-centered innovation is defining the...

    Leading the future of Intelligent Commercialization™: Where proprietary data, tech, and AI meet expert insight

    Inizio is leading the way in Intelligent Commercialization™ by uniting proprietary AI-powered platforms, deep scientific expertise, and proven governance to unlock measurable, lasting value at every stage of commercialization.